US specialist pharma company Acorda is to acquire Biotie for $363 million, a move which it hopes will make it a leader in Parkinson's disease treatments.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.